Sandra Calvin Sells 15,000 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the sale, the chief accounting officer now directly owns 54,927 shares in the company, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Sandra Calvin also recently made the following trade(s):

• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX opened at $17.28 on Friday. The stock has a market cap of $1.35 billion, a PE ratio of -3.80 and a beta of 0.69. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $20.33. The firm has a fifty day moving average price of $18.11 and a 200-day moving average price of $13.39. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. The business had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. Travere Therapeutics’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.17) EPS. Equities analysts anticipate that Travere Therapeutics, Inc. will post -3.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TVTX has been the subject of a number of research reports. Leerink Partners reiterated an “outperform” rating and set a $20.00 target price on shares of Travere Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reduced their price objective on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Wedbush raised their target price on Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group reduced their price target on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, September 30th. Finally, Guggenheim raised their price objective on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Institutional Trading of Travere Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its stake in Travere Therapeutics by 18.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 264,816 shares of the company’s stock worth $2,177,000 after purchasing an additional 41,048 shares during the period. Panagora Asset Management Inc. purchased a new stake in Travere Therapeutics in the 2nd quarter worth $747,000. Rhumbline Advisers boosted its holdings in shares of Travere Therapeutics by 17.4% during the 2nd quarter. Rhumbline Advisers now owns 125,660 shares of the company’s stock valued at $1,033,000 after purchasing an additional 18,645 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Travere Therapeutics by 202.6% during the second quarter. Acadian Asset Management LLC now owns 144,901 shares of the company’s stock valued at $1,190,000 after purchasing an additional 97,020 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in shares of Travere Therapeutics by 240.6% in the second quarter. Quest Partners LLC now owns 14,336 shares of the company’s stock worth $118,000 after purchasing an additional 10,127 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.